Last week’s hot topic on pulmonary fibrosis was IPF Drug in Phase 2 Study Reduced Lung Fibrosis, Improved Function in 35% of Patients written by Margarida Azevedo.
FibroGen, Inc., recently disclosed potentially groundbreaking results from a Phase 2 clinical trial evaluating the efficacy of the company’s investigational drug FG-3019 in the treatment of idiopathic pulmonary fibrosis (IPF). Data indicated that the monoclonal antibody agent was able to reduce lung fibrosis in a portion of the IPF patients enrolled, to improve overall lung function.
The results were published in the European Respiratory Journal, in an article titled “FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in IPF.”
Based on the results, the company is planning further investigation of FG-3019 in another Phase 2 study, this time placebo-controlled. The clinical trial (NCT01890265) is now recruiting participants at 25 sites across the U.S. and one in Quebec City, Canada.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?